Pfizer Inc. and French vaccine maker Valneva SE announced that their investigational 6‑valent Lyme disease vaccine candidate PF‑07307405 (LB6V, formerly VLA15) achieved a 73.2% efficacy rate measured 28 days after the fourth dose in the Phase 3 VALOR trial. A secondary analysis that counted cases from 1 day after the fourth dose reported a slightly higher efficacy of 74.8%. The trial enrolled roughly 9,000 participants aged five years and older across the United States and recorded no serious adverse events, underscoring a strong safety profile.
The study’s primary endpoint—defined as a 95% confidence‑interval lower bound greater than 20%—was not met. Pfizer attributed the miss to a lower-than‑expected incidence of Lyme disease during the trial period, a factor that made the pre‑specified statistical threshold difficult to reach. The company emphasized that the observed efficacy remains clinically meaningful and that the vaccine still represents a significant advance in Lyme disease prevention.
"Lyme disease can cause potentially serious consequences – where individuals and families face symptoms that can disrupt daily life, work, and long‑term health – and there is currently no vaccine available. The efficacy shown in the VALOR study of more than 70% is highly encouraging and creates confidence in the vaccine’s potential to protect against this disease that can be debilitating," said a Pfizer spokesperson. "Given the clinically meaningful efficacy and the fact that the 95% confidence interval lower bound was above 20 in the second pre‑specified analysis, Pfizer is confident in the vaccine’s potential and is planning submissions to regulatory authorities," added another Pfizer representative. "These results bring us a step closer to our goal of delivering a much‑needed vaccine to help protect against Lyme disease. We are grateful to our partner Pfizer for their strong commitment which we both share in developing this vaccine as quickly as possible," said Thomas Lingelbach, CEO of Valneva.
The vaccine’s potential to become the first commercially available Lyme disease vaccine could unlock a multi‑billion‑dollar revenue stream, but the missed primary endpoint introduces regulatory uncertainty. Investors reacted negatively, citing the statistical miss as a key concern. RBC Capital Markets analysts noted that the failure to meet the confidence‑interval threshold could delay regulatory approval and affect commercial launch timelines, tempering enthusiasm for the vaccine’s market prospects.
Valneva’s broader financial picture adds context to the announcement. The company reported a net loss of €115.19 million for 2025, a sharp increase from a €12.25 million loss in 2024, and guided 2026 revenues to €155–170 million. The Lyme disease vaccine market is projected to grow from $1.12 billion in 2025 to $1.57 billion by 2030, positioning the vaccine as a potentially transformative product for Valneva’s pipeline.
Investors reacted negatively, citing the missed primary endpoint as a key concern. RBC Capital Markets analysts highlighted that the statistical miss could delay regulatory approval and affect commercial launch timelines, tempering enthusiasm for the vaccine’s market prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.